A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
Long-term commitment, high ambitions
Neurosciences and functional rehabilitation are medical specialties involving the study of diseases of the central nervous system. The Group’s in-depth knowledge of type-A botulinum toxin extends across the entire lifecycle. A leader in toxins and recombinant toxin engineering, Ipsen has a wide range of additional expertise and technologies to support the consolidation of its innovative toxin platform, particularly in liquid ready-to-use formulations and to develop new products from toxins.
Dysport®: one product, a range of indications
Dysport® is based on botulinum toxin ‘Type A’, a compound based on a bacterium that inhibits the transmission of nerve impulses to the muscle. Botulinum toxin injections cause contracted muscles to relax, enabling patients to return to a number of their daily activities, while relieving them and improving their quality of life.
Dysport® is administered by practitioners in neurosciences and other specialist medicine areas. There are a diverse range of drug indications:
- spasticity (exaggerated muscular tone following a stroke for example),
- cervical dystonia (a chronic condition in which the neck is deviated),
- hemifacial spasm (a movement disorder characterized by contractions of the muscles located on one side of the face that can lead to disfigurement),
- blepharospasm (involuntary contraction of the eyelids).
For aesthetic indications, Ipsen and Galderma entered in July 2014 into an exclusive partnership for the development and marketing of neurotoxins in aesthetic medicine in the United States, Canada, Brazil, and Europe (excluding, Russia). The agreement also set out the terms of their collaboration on the development and marketing of new neurotoxins, including their respective liquid formulations.
In certain countries, Dysport® is also prescribed for the treatment of hyperhidrosis, characterized by excessive perspiration for which conventional solutions are hardly efficient – a market which shows significant potential.
Prospects for new applications and formulations
The acquisition in 2013 of Ipsen Bioinnovation (formerly Syntaxin), a leader in the engineering of recombinant toxins, allows Ipsen access to innovative technologies and to develop a complete portfolio of toxins. The unique technology of this platform provides broad opportunities for collaborative research (e.g. with Harvard University) and development. These next generation toxins have broad potential for therapeutic applications that will bring innovative solutions to address the needs of patients.
Ipsen has made it a priority to advance the treatment of spasticity in multiple sclerosis. In January 2014, GW Pharmaceuticals Plc granted Ipsen promotion and distribution rights in Latin America (excluding Mexico and the Caribbean) for Sativex®, a sublingual cannabis extract spray for the treatment of spasticity in patients with multiple sclerosis. In addition, Canbex (a spin-off from University College London) granted Ipsen in February 2015 an option giving Ipsen the exclusive right to purchase 100% of Canbex shares, upon completion of the phase IIa study of Canbex’s lead candidate drug (VSN16R) for the treatment of spasticity in people with multiple sclerosis. This innovative molecule is administered orally.
Steady international growth
First launched in the United Kingdom in 1991, Dysport® is available globally. At the end of 2012, Dysport® had marketing authorizations in more than 80 countries, including in the United States where it was authorized in 2009. Ipsen is currently expanding sales of the product in emerging markets (Brazil and South Korea amongst others) primarily for aesthetic indications.
In July 2016, the U.S. Food and Drug Administration (FDA) has also approved Dysport® for the treatment of pediatric lower limb (PLL) spasticity in children two years of age and older. Dysport® is the first and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity.
Sales in neurosciences in 2016
(18.1% of sales in 2016)
Expertise in neurotoxins
Patents in neurology
- Opheim A, et al. (2014). Upper-Limb Spasticity During the First Year After Stroke. Stroke Arm Longitudinal Study at the University of Gothenburg. American Journal of Physical Medicine & Rehabilitation, 93: 884:896
- “Traumatic Brain Injury in the United States: Fact Sheet.” Centers for Disease Control and Prevention. 6 June 2015. http:www.cdc.gov/traumaticbraininjury/
get_the_facts.html, 24 February 2014
- Ganish S, et al. (2013). Medical Comorbidities in Disorders of Consciousness Patients and Their Association with Functional Outcomes. Archives of Physical Medicine and Rehabilitation, 94: 1899-907